Merck & Co., Inc. $MRK Shares Sold by Cantor Fitzgerald Investment Advisors L.P.

Cantor Fitzgerald Investment Advisors L.P. lessened its position in Merck & Co., Inc. (NYSE:MRK) by 65.9% in the 3rd quarter, Holdings Channel reports. The firm owned 37,907 shares of the company’s stock after selling 73,104 shares during the period. Cantor Fitzgerald Investment Advisors L.P.’s holdings in Merck & Co., Inc. were worth $5,508,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MRK. BlackRock Inc. increased its position in shares of Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after acquiring an additional 1,073,507 shares in the last quarter. State Street Corp raised its holdings in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after purchasing an additional 1,087,583 shares during the period. Wellington Management Group LLP boosted its stake in shares of Merck & Co., Inc. by 2.3% during the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after acquiring an additional 1,934,312 shares during the period. Bank of America Corp DE raised its position in shares of Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares during the period. Finally, Invesco Ltd. lifted its position in Merck & Co., Inc. by 3.5% during the fourth quarter. Invesco Ltd. now owns 20,546,185 shares of the company’s stock worth $2,162,691,000 after acquiring an additional 701,249 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the sale, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Richard R. Deluca sold 20,784 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the transaction, the executive vice president directly owned 134,703 shares in the company, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by insiders.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $146.01 on Friday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The stock has a 50-day moving average of $145.60 and a 200-day moving average of $129.24. The company has a market cap of $360.22 billion, a PE ratio of 116.81, a P/E/G ratio of 6.71 and a beta of 0.21. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the prior year, the company earned $2.13 earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported promising skin-cancer trial results involving Keytruda and a personalized mRNA vaccine. Positive clinical data could strengthen confidence in Merck’s oncology franchise and support longer-term growth. Merck reports promising skin cancer trial results
• Positive Sentiment: Merck is scheduled to present first-time pivotal Phase 3 oncology results at ESMO 2026, including melanoma and endometrial-cancer programs, alongside an oncology investor event. The disclosures may demonstrate progress in replacing or extending revenue from existing cancer therapies. Merck ESMO 2026 oncology pipeline preview
• Positive Sentiment: Merck’s continued uptrend has encouraged options traders to consider bullish strategies, indicating that some market participants expect further gains. Options activity, however, can amplify volatility and does not by itself change the company’s fundamentals. Merck bullish options strategy
• Neutral Sentiment: Merck’s investment narrative has shifted toward oncology and other growth opportunities as investors look beyond challenges affecting Gardasil, particularly in China. The strategy could improve diversification, but execution and pipeline commercialization remain key.
• Neutral Sentiment: Merck is being compared favorably with other pharmaceutical companies on dividend sustainability and cash generation, though the articles do not identify a major new dividend announcement. Merck versus Amgen dividend comparison
• Negative Sentiment: After rising more than 38% in 2026, Merck trades at a substantially higher forward earnings multiple than in late 2025. Analysts warn that the market may already be pricing in significant pipeline success, leaving less room for upside and greater sensitivity to disappointing trial data. Merck valuation and rally analysis

Analysts Set New Price Targets

Several research firms recently commented on MRK. Sanford C. Bernstein upped their price target on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a research note on Tuesday, August 4th. UBS Group increased their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Bank of America boosted their price target on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Argus lifted their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Finally, Morgan Stanley decreased their price objective on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Seventeen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $151.92.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.